Skip to content
Menu

Radiopharm Theranostics Limited RADX

Full chart Compare
Set alert

Price alert · RADX

All alert types
0.67 USD -0.01 (-1.77%)

Regular-session close

0.68 +0.01 +1.37%

After hours · Nov 19, 4:00 PM ET

0.6319 Day range 0.70
0.671 52-week range 10.63
YTD
-87.11%
1 year
-85.43%

5D -0.1200 (-15.79%)

0.70000.8000FriMonTueWedThu0.6400
Market cap
10.57M
Revenue (ttm)
1.96M
EPS (ttm)
-3.57
YTD return
-87.11%
1-year return
-85.43%
50-day average
7.67
200-day average
7.67
Volume
27.20K
Avg volume
56.72K
Open
0.6319
Previous close
0.6851
Day's range
0.6319 – 0.70
52-week range
0.671 – 10.63
Beta
0.85

Key statistics

Enterprise value
9.52B
Price / book
69.02
Free cash flow
-12.04M
Total cash
18.58M
Return on equity
-131.49%

Fundamental scorecard

3 of 25 checks passed on RADX’s reported financials

ValueGrowthProfitabilityHealthDividend

3of 25 checks passed

  • Value 0 of 5
  • Growth 0 of 5
  • Profitability 1 of 5
  • Financial health 2 of 5
  • Dividend 0 of 5

Statements to Jun 30, 2026.

Financials — quick view

All financials
RADX Revenue — annual 2.77M
RADX Net income — annual -54.53M
RADX EPS — annual -5.37

About Radiopharm Theranostics Limited

Radiopharm Theranostics Limited engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical needs. It develops RAD 204, a programmed death-ligand 1 (PD-L1) for the treatment of non-small cell lung cancer (NSCLC); RAD 202, a human epidermal growth factor receptor 2 (HER2) to treat breast cancer and other solid tumors; and RAD 301, a diagnostic radiopharmaceutical targeting avß6 integrin in pancreatic ductal adenocarcinoma patients. The company also develops RAD 302, an avß6-integrin targeting agent for the treatment of multiple cancer types; RAD 101 and RAD 102 for brain metastases; RAD 402 to treat advanced prostate cancer; and RV01 for multiple solid tumors. The company was incorporated in 2021 and is based in Carlton, Australia.

Sector
Healthcare
Industry
Biotechnology
Country
Australia

News

Your note

Sign in to keep a note on RADX — it syncs with the Stock Master app.